Cargando…

Is there a role for immunotherapy in HER2-positive breast cancer?

Although the prognosis and prediction of therapeutic benefit for breast cancer patients overexpressing the human epidermal growth factor receptor 2 (HER2) have dramatically changed with the administration of anti-HER2-targeted therapies, HER2-positive metastatic breast cancer is still an incurable d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holgado, Esther, Perez-Garcia, Jose, Gion, Maria, Cortes, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093898/ https://www.ncbi.nlm.nih.gov/pubmed/30131972 http://dx.doi.org/10.1038/s41523-018-0072-8

Ejemplares similares

Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
por: Lebert, Julie, et al.
Publicado: (2022)

Immunotherapy for HER-2 positive breast cancer
por: Yang, Tingting, et al.
Publicado: (2023)

CXCR4 antagonists for treatment of breast cancer
por: Cortés, Javier, et al.
Publicado: (2018)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

Immunotherapies against HER2-Positive Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2023)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”
por: Gion, Maria, et al.
Publicado: (2022)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno, I, et al.
Publicado: (2015)

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
por: Martin-Castillo, Begoña, et al.
Publicado: (2015)

Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients
por: Rennhack, Jonathan, et al.
Publicado: (2015)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
por: Pérez-García, José Manuel, et al.
Publicado: (2022)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
por: Arab, Atefeh, et al.
Publicado: (2020)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
por: Ayoub, Nehad M, et al.
Publicado: (2019)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Targeting HER2(+) breast cancer: the TBK1/IKKε axis
por: Jiang, Zhe, et al.
Publicado: (2014)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy
por: Sun, Yajie, et al.
Publicado: (2021)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Brasó-Maristany, Fara, et al.
Publicado: (2020)

Engineering dendritic cell vaccines to improve cancer immunotherapy
por: Perez, Caleb R., et al.
Publicado: (2019)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects
por: Gion, María, et al.
Publicado: (2021)

Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers
por: López-García, M. Ángeles, et al.
Publicado: (2020)

Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer
por: Yuan, Peng, et al.
Publicado: (2017)

Preclinical and clinical efficacy of trastuzumab-deruxtecan in breast cancer brain metastases: a new insight on central nervous system activity
por: Batista, Marta Vaz, et al.
Publicado: (2023)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra, Drew R, et al.
Publicado: (2014)

Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
por: Cuyàs, Elisabet, et al.
Publicado: (2020)

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
por: de la Cruz-Merino, L., et al.
Publicado: (2022)

HER2/positive and HER2/low in inflammatory breast cancer recurrence
por: Movchan, Oleksii Volodimirovich, et al.
Publicado: (2022)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
por: Martin-Castillo, Begoña, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dctc1r6qo3oe28r56t5tqpu796